Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.

Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasuryPRINCETON, N.J., July 14, 2025 ( ...

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness ...

To boost mood and manliness, men are spending lots of money on the hormone testosterone—yet they may see trouble instead of ...

Investing.com -- Citius Oncology, Inc. (NASDAQ: CTOR) stock rose 4.1% after announcing a distribution services agreement with Cencora for its FDA-approved immunotherapy LYMPHIR.

PD-L1 is the target of several clinically approved cancer immunotherapies. By linking the STING agonist to this bivalent nanobody – with one end binding to albumin and the other to PD-L1 – they found ...

SNMMI annual meeting featured a radiotheranostics session and a presentation by Dr. Xuejen Wen discussing the development of PSMA targeting radioligand 161 Tb-LNC1011 for prostate cancer theranostics.

Nanoparticles (NPs) are materials whose dimensions range from 1 to 1,000 nanometers (nm). Due to their nano-scale dimensions and tunable material properties, NPs have gained interest in the global ...

ACROBiosystems has developed a series of specialized proteases for the screening and validation of ADC linkers, focusing on ...

Citius Oncology, Inc. (NASDAQ:CTOR) saw its stock rise 4.1% after announcing a new distribution services agreement with Cencora to broaden the reach of its FDA-approved immunotherapy, LYMPHIR. The ...

Peptides have emerged as a fascinating area of scientific inquiry due to their potential to modulate various physiological ...

The Semaglutide peptide has emerged as a compelling subject in biochemical and physiological research due to its potential ...